Alnylam Pharmaceuticals, Inc. and Akshay K. Vaishnaw, M.D., Ph.D. entered into a letter agreement, whereby Dr. Vaishnaw will leave his current position as President of the Company and transition to a part-time role as Chief Innovation Officer, effective October 2, 2023.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
147.2 USD | +0.20% | -1.14% | -22.85% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.85% | 18.59B | |
+47.13% | 56.69B | |
-2.68% | 41B | |
+38.14% | 38.11B | |
-11.22% | 26.89B | |
+15.72% | 25.59B | |
+0.06% | 12.39B | |
+26.80% | 11.99B | |
+22.85% | 11.88B | |
-10.37% | 10.89B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023